EP4683907A1 — Solid state forms of pirtobrutinib and process for the preparation of intermediate thereof
Assigned to Dr Reddys Laboratories Ltd · Expires 2026-01-28 · 0y expired
What this patent protects
Aspects of the present application relates to solid state forms of Pirtobrutinib such as novel crystalline form P1, amorphous solid dispersions comprising Pirtobrutinib and pharmaceutically acceptable carriers and processes thereof, wherein the pharmaceutically acceptable carrier…
USPTO Abstract
Aspects of the present application relates to solid state forms of Pirtobrutinib such as novel crystalline form P1, amorphous solid dispersions comprising Pirtobrutinib and pharmaceutically acceptable carriers and processes thereof, wherein the pharmaceutically acceptable carrier is selected from the group consisting of HPMC phthalate, HPC, Eudragit L100, microcrystalline cellulose, carboxymethyl cellulose, mannitol, Neusilin, cellulose acetate phthalate, polyvinyl alcohol, polylactic-co-glycolic acid, polyvinyl acetate phthalate, sodium alginate, beta cyclodextrin, and mixtures thereof. Aspects of the present application relates to process for the preparation of [(1S)-2,2,2-trifluoro-l-methyl- ethyl]hydrazine or its salts.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.